To date, five muscarinic acetylcholine receptor (mAChR) subtypes have been identified (M1-M5) and play important roles in mediating the actions of ACh in the peripheral and central nervous systems. Of these, M1 and M4 are the most heavily expressed in the CNS and represent attractive therapeutic targets for cognition, Alzheimer's disease, and schizophrenia. In contrast, the adverse effects of cholinergic agents are thought to be primarily due to activation of peripheral M2 and M3 mAChRs. Due to the high sequence homology and conservation of the orthosteric ACh binding site among the mAChR subtypes, development of chemical agents that are selective for a single subtype has been largely unsuccessful, and in the absence of highly selective activators of M4, it has been impossible to test the role of selective M4 activation. Clinical trials with xanomeline, a M1/M4-preferring orthosteric agonist, demonstrated efficacy as both a cognition-enhancing agent and an antipsychotic agent. In follow-up studies in rats, xanomeline displayed an antipsychotic-like profile comparable to clozapine. However, a long standing question concerned whether or not the antipsychotic efficacy or antipsychotic-like activity in animal models is mediated by activation of M1, M4, or a combination of both receptors. Data from mAChR knockout mice led to the suggestion that a selective M1 agonist would be beneficial for cognition, whereas an M4 agonist would provide antipsychotic activity for the treatment of schizophrenia. This proposal is further supported by recent studies demonstrating that M4 receptors modulate the dynamics of cholinergic and dopaminergic neurotransmission and that loss of M4 function results in a state of dopamine hyperfunction. These data, coupled with findings that schizophrenic patients have altered hippocampal M4 but not M1 receptor expression, suggest that selective activators of M4 may provide a novel treatment strategy for schizophrenia patients. However, multiple studies suggest that M1 may also play an important role in the antipsychotic effects of mAChR agonists and that the relative contributions of M1 and M4 to the antipsychotic efficacy of xanomeline or antipsychotic-like effects of this compound in animal models are not known. However, highly selective centrally penetrant activators of either M1 or M4 have not been available, making it impossible to determine the in vivo effects of selective activation of these receptors. The purpose of this experiment was to test compounds of interest for their ability to modulate [3H]N-methyl-scopolamine ([3H]-NMS) binding at the rat M4 muscarinic receptor. Competition binding assays were carried out essentially as described in with 25 mg of membrane protein prepared from CHO-K1 cells stably expressing rat M4 and 0.1nM [3H]-N-methylscopolamine (GE Healthcare) in a final volume of 1mL.  Non-specific binding was determined in the presence of 1 mM atropine.   A full atropine CRC was determined as a positive control. The compounds did not affect binding of the orthosteric ligand [3H]-NMS suggesting an allosteric modulation for the lead compounds. 'Outcome' was assigned as 'Inactive' and 'Score' was assigned as "0'.
bao:BAO_0000541 "625" ; # "is counter assay of" -> "625"
bao:BAO_0000812 "2616" ; # "has summary assay" -> "2616"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0000154 bao:BAO_0000543 ; # "has orthogonal assay design" -> "orthogonal assay design"
bao:BAO_0000205 bao:BAO_0000366 ; # "has assay format" -> "cell-free format"
bao:BAO_0000205 bao:BAO_0000249 ; # "has assay format" -> "cell membrane format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000284 ; # "has participant" -> "G protein coupled receptor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0002776 ; # "is bioassay type of" -> "radioligand binding assay"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000212 bao:BAO_0000402 ; # "has assay method" -> "radioligand binding method"
bao:BAO_0000207 bao:BAO_0000401 ; # "has detection method" -> "filter assay"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Novel allosteric modulators of the M4 muscarinic receptor" ; # "screening campaign name" -> "Novel allosteric modulators of the M4 muscarinic receptor"
bao:BAO_0002853 "Discovery of a Highly Selective in vitro and in vivo M4 Positive Allosteric Modulator (PAM): NMS Competition at rM4" ; # "has assay title" -> "Discovery of a Highly Selective in vitro and in vivo M4 Positive Allosteric Modulator (PAM): NMS Competition at rM4"
bao:BAO_0003105 <http://purl.obolibrary.org/obo/GO_0005488> ; # "has function" -> "binding"
bao:BAO_0002867 bao:BAO_0000513 ; # "has assay footprint" -> "96 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BA0_0090012 "Atropine concentration series" ; # "has participant" -> "Atropine concentration series"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 "vehicle" ; # "has participant" -> "vehicle"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
bao:BAO_0000740 "Atropine 1 millimolar" ; # "has assay control" -> "Atropine 1 millimolar"
bao:BAO_0000740 bao:BAO_0000334 ; # "has assay control" -> "background control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Colleen Niswender" ; # "material entity assay provider" -> "Colleen Niswender" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BAO_0000118 "0.10%" ; # "DMSO" -> "0.10%"
bao:BAO_0002000 bao:BAO_0000829 ; # "has measured entity" -> "[3H]N-methylscopolamine" || bao:BAO_0003102 bao:BAO_00020138 ; # "has role" -> "potentiator"
bao:BA0_0090012 "Muscarinic acetylcholine receptor M4" ; # "has participant" -> "Muscarinic acetylcholine receptor M4"
bao:BAO_0002004 <http://purl.obolibrary.org/obo/CLO_0002462> ; # "has cell line" -> "CHO-K1 cell"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_10116> ; # "has organism" -> "Rattus norvegicus"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P08485" ; # "uniprot ID" -> "P08485"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10116" ; # "NCBI taxonomy ID" -> "10116"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10% fetal bovine serum" ; # "material entity culture serum" -> "10% fetal bovine serum" || bao:BAO_0003102 bao:BAO_0002596 ; # "has role" -> "culture serum"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"DMEM with 10% FBS, 2 mM GlutaMax I, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 20 mM HEPES, and 400 microg/ml G418 sulfate\"" ; # "material entity culture medium" -> ""DMEM with 10% FBS, 2 mM GlutaMax I, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 20 mM HEPES, and 400 microg/ml G418 sulfate"" || bao:BAO_0003102 bao:BAO_0000114 ; # "has role" -> "culture medium"
bao:BAO_0002922 "\"20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2\"" ; # "has assay medium" -> ""20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2""
bao:BAO_0002922 bao:BAO_0000596 ; # "has assay medium" -> "assay medium"
bao:BAO_0000212 bao:BAO_0000246 ; # "has assay method" -> "stable transfection"
bao:BAO_0000550 "Expressing rat muscarinic M4 receptor" ; # "DNA construct" -> "Expressing rat muscarinic M4 receptor"
bao:BAO_0003105 "\"cholinergic receptor, muscarinic 4\"" ; # "has function" -> ""cholinergic receptor, muscarinic 4""
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "25111" ; # "construct gene ID" -> "25111"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0003105 bao:BAO_0000956 ; # "has function" -> "Lipofectamine 2000" || bao:BAO_0003102 bao:BAO_0002105 ; # "has role" -> "transfection agent"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0000829 ; # "has participant" -> "[3H]N-methylscopolamine"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0002153 ; # "has signal direction" -> "signal increase corresponding to inhibition"
bao:BAO_0000737 bao:BAO_0000746 ; # "has manufacturer" -> "GE Healthcare" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0001036 ; # "uses detection instrument" -> "TopCount NXT Microplate Scintillation Luminescence Counter"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000188 ; # "has endpoint" -> "EC50"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000062> ; # "has concentration unit" -> "molar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "26" ; # "PubChem TID" -> "26"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "11" ; # "has concentration-point number" -> "11"
bao:BAO_0002845 "2" ; # "has repetition point-number" -> "2"
bao:BAO_0000196 bao:BAO_0000537 ; # "has mode of action" -> "allosteric binding"
bao:BAO_0002864 bao:BAO_0000533 ; # "has repetition throughput" -> "multiple repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "mp" ; # "Annotated by" -> "mp"
